Locket Healthcare Exports Skin Regeneration Treatment Platform to Brazil

[Asia Economy Reporter Byun Seon-jin] Biohealthcare company Rokit Healthcare announced on the 20th that it has signed a supply contract worth approximately KRW 100 billion (USD 71 million) over five years for its skin regeneration treatment platform with Brazilian medical device distributor '1000medic.'

Rokit Healthcare received regulatory approval from the Brazilian Health Regulatory Agency (ANVISA) last May. Since then, through its partner 1000medic, it has signed contracts with 10 sub-distributors in 5 cities and began sales activities in September. This month, the company is preparing for the first commercial treatment at Brazil's leading hospital chain group, 'D’or hospital.'

Starting with Brazil, Rokit Healthcare is accelerating its entry into the Latin American market. A company representative stated, “Following Brazil, we signed a contract worth approximately KRW 15 billion over five years with Paraguay's Bioethic, and local approval is expected to be completed by the end of October, leading to imminent commercialization. In particular, a diabetic foot care center invested in by Bioethic was established at the end of September, where clinical trials involving about 20 participants are underway, and commercialization is also expected to take place at this center.”

The company plans to sign a contract with Argentina's local pharmaceutical company 'Varipharma' within this month and expand the skin regeneration treatment platform to other Latin American countries such as Uruguay and Costa Rica in November.

This content was produced with the assistance of AI translation services.